Monoamine oxidase-B inhibition in the treatment of Parkinson's disease (Q37016034)

17 August 2017

1 reference

title

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease (English)

1 reference

17 August 2017

1 reference

1

Hubert H Fernandez

1 reference

17 August 2017

Jack J Chen

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

27

1 reference

17 August 2017

issue

12 Pt 2

1 reference

17 August 2017

page(s)

174S-185S

1 reference

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Pharmacotherapy for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Deprenyl in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Deprenyl suppresses the oxidant stress associated with increased dopamine turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Mortality in people taking selegiline: observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

The essentiality of Bcl-2, PKC and proteasome–ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12PART2.174S

10.1592/PHCO.27.12PART2.174S

21 January 2018

Identifiers

DOI

1 reference

release_ttll7kj6jza6rdzcat6ega6bzy

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ttll7kj6jza6rdzcat6ega6bzy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference